Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia

References

• Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109:874–885.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Schneider F, Hoster E, Schneider S, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol. 2012;91:9–18.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yin J, He Q, et al. Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies. Leuk Res. 2018;70:8–12.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Pettirossi V, Thiede C, et al. CD34 + cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010;116:3907–3922.
   PubMed Web of Science ®Google Scholar
• Rose D, Haferlach T, Schnittger S, et al. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31:11–17.
   PubMed Web of Science ®Google Scholar
• La Manna S, Florio D, Di Natale C, et al. Conformational consequences of NPM1 rare mutations: An aggregation perspective in acute myeloid leukemia. Bioorg Chem. 2021;113:104997.
   PubMed Web of Science ®Google Scholar
• Jeon Y, Seo SW, Park S, et al. Identification of two novel NPM1 mutations in patients with acute myeloid leukemia. Ann Lab Med. 2013;33:60–64.
   PubMed Web of Science ®Google Scholar
• Beziat G, Tavitian S, Bertoli S, et al. Dactinomycin in acute myeloid leukemia with NPM1 mutations. Eur J Haematol. 2020;105:302–307.
   PubMed Web of Science ®Google Scholar
• Helbig G, Wozniczka K, Wieclawek A, et al. Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukemia - preliminary report. Contemp Oncol (Pozn). 2014;18:241–245.
   PubMedGoogle Scholar
• Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740–3746.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Jädersten M, Deneberg S, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv. 2020;4:1094–1101.
   PubMed Web of Science ®Google Scholar
• Cappelli LV, Meggendorfer M, Dicker F, et al. DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern. Leukemia. 2019;33:2741–2746.
   PubMed Web of Science ®Google Scholar
• Yang X, Shi J, Zhang X, et al. Biological and clinical influences of NPM1 in acute myeloid leukemia patients with DNMT3A mutations. Cancer Manag Res. 2018;10:2489–2497. doi:10.2147/CMAR.S166714.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28:3636–3643.
   PubMed Web of Science ®Google Scholar
• Mitrea DM, Grace CR, Buljan M, et al. Structural polymorphism in the N-terminal oligomerization domain of NPM1. Proc Natl Acad Sci U S A. 2014;111:4466–4471.
   PubMed Web of Science ®Google Scholar
• Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437:147–153.
   PubMed Web of Science ®Google Scholar
• Nachmani D, Bothmer AH, Grisendi S, et al. Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita. Nat Genet. 2019;51(10):1518–1529.
   PubMed Web of Science ®Google Scholar
• Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 1999;8:905–912.
   PubMed Web of Science ®Google Scholar
• Luchinat E, Chiarella S, Franceschini M, et al. Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf. FEBS J. 2018;285:832–847.
   PubMed Web of Science ®Google Scholar
• Lindström MS. NPM1/B23: a multifunctional chaperone in ribosome biogenesis and Chromatin remodeling. Biochem Res Int. 2011;2011:195209.
   PubMedGoogle Scholar
• Cela I, Di Matteo A, Federici L. Nucleophosmin in its interaction with ligands. Int J Mol Sci. 2020;21:4885.
   PubMed Web of Science ®Google Scholar
• Liso A, Castiglione F, Cappuccio A, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 2008;93:1219–1226.
   PubMed Web of Science ®Google Scholar
• Dvorakova D, Racil Z, Borsky M, et al. Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. Leuk Lymphoma. 2013;54:1056–1060.
   PubMed Web of Science ®Google Scholar
• Sportoletti P, Varasano E, Rossi R, et al. The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. Blood. 2013;121:3447–3458.
   PubMed Web of Science ®Google Scholar
• Martínez-Losada C, Serrano-López J, Serrano-López J, et al. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. Haematologica. 2018;103:e400–e403.
   PubMed Web of Science ®Google Scholar
• Patel JL, Schumacher JA, Frizzell K, et al. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia. Leuk Res. 2017;56:7–12.
   PubMed Web of Science ®Google Scholar
• Loberg MA, Bell RK, Goodwin LO, et al. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia. 2019;33:1635–1649.
   PubMed Web of Science ®Google Scholar
• Alpermann T, Schnittger S, Eder C, et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica. 2016;101:e55–e58.
   PubMed Web of Science ®Google Scholar
• Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107:4514–4523.
   PubMed Web of Science ®Google Scholar
• Chiarella S, De Cola A, Scaglione GL, et al. Nucleophosmin mutations alter its nucleolar localization by impairing G-quadruplex binding at ribosomal DNA. Nucleic Acids Res. 2013;41:3228–3239.
   PubMed Web of Science ®Google Scholar
• Kunchala P, Kuravi S, Jensen R, et al. When the good go bad: mutant NPM1 in acute myeloid leukemia. Blood Rev. 2018;32:167–183.
   PubMed Web of Science ®Google Scholar
• Bailey GD, Doolan L, Baskar A, et al. Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukemia. Sci Rep. 2020;10:17695.
   PubMed Web of Science ®Google Scholar
• Tang Y, Tao Y, Wang L, et al. NPM1 mutant maintains ULK1 protein stability via TRAF6-dependent ubiquitination to promote autophagic cell survival in leukemia. FASEB J. 2021;35:e21192.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang L, Yang Z, et al. Glycolytic enzyme PKM2 mediates autophagic activation to promote cell survival in NPM1-mutated leukemia. Int J Biol Sci. 2019;15:882–894.
   PubMed Web of Science ®Google Scholar
• Di Matteo A, Franceschini M, Paiardini A, et al. Structural investigation of nucleophosmin interaction with the tumor suppressor Fbw7γ. Oncogenesis. 2017;6:e379.
   PubMed Web of Science ®Google Scholar
• Sportoletti P, Celani L, Varasano E, et al. GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. Leukemia. 2019;33:1827–1832.
   PubMed Web of Science ®Google Scholar
• Wang AJ, Han Y, Jia N, et al. NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia. Leukemia. 2020;34:1278–1290.
   PubMed Web of Science ®Google Scholar
• Ando K, Tsushima H, Matsuo E, et al. Mutations in the nucleolar phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcription factor MEF/ELF4 in leukemia cells and potentiates transformation. J Biol Chem. 2013;288:9457–9467.
   PubMed Web of Science ®Google Scholar
• Johansson H, Simonsson S. Core transcription factors, Oct4, Sox2 and Nanog, individually form complexes with nucleophosmin (Npm1) to control embryonic stem (ES) cell fate determination. Aging (Albany NY). 2010;2:815–822.
   PubMedGoogle Scholar
• Brunetti L, Gundry MC, Sorcini D, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34:499–512. e9.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Kennedy A, Zhou X, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia. 2007;21:2000–2009.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao C, Zhao J, et al. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival. Theranostics. 2018;8:4359–4371.
   PubMed Web of Science ®Google Scholar
• Wiktorin HG, Nilsson T, Jansson A, et al. Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia. Exp Hematol Oncol. 2015;5:25.
   PubMedGoogle Scholar
• Ogawara Y, Katsumoto T, Aikawa Y, et al. IDH2 and NPM1 mutations cooperate to activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia. Cancer Res. 2015;75:2005–2016.
   PubMed Web of Science ®Google Scholar
• Dovey OM, Cooper JL, Mupo A, et al. Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia. Blood. 2017;130:1911–1922.
   PubMed Web of Science ®Google Scholar
• Havelange V, Ranganathan P, Geyer S, et al. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 2014;123:2412–2415.
   PubMed Web of Science ®Google Scholar
• Papaioannou D, Petri A, Dovey OM, et al. The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. Nat Commun. 2019;10:5351.
   PubMed Web of Science ®Google Scholar
• Zhu G, Luo H, Feng Y, et al. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nat Commun. 2021;12:1956.
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Geromin A, Damiani D, et al. Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1 + cytogenetically normal acute myeloid leukemia. Am J Hematol. 2012;92:E45–E47.
   Google Scholar
• Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089.
   PubMed Web of Science ®Google Scholar
• Guièze R, Cornillet-Lefebvre P, Lioure B, et al. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study. Am J Hematol. 2012;87:1052–1056.
   PubMed Web of Science ®Google Scholar
• Huang Y, Hu J, Lu T, et al. Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis. Cancer Manag Res. 2019;11:4129–4142.
   PubMed Web of Science ®Google Scholar
• Röllig C, Bornhäuser M, Kramer M, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol. 2015;33:403–410.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Labopin M, Meloni G, et al. Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission. Haematologica. 2013;98:e12–e14.
   PubMed Web of Science ®Google Scholar
• Boddu P, Kantarjian H, Borthakur G, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1:1546–1550.
   PubMed Web of Science ®Google Scholar
• Prata PH, Bally C, Prebet T, et al. NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. Haematologica. 2018;103:e455–e457.
   PubMed Web of Science ®Google Scholar
• Wei A, Tan P, Perruzza S, et al. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukemia. Br J Haematol. 2015;169:199–210.
   PubMed Web of Science ®Google Scholar
• Perriello VM, Gionfriddo I, Rossi R, et al. CD123 is consistently expressed on NPM1-mutated AML cells. Cancers (Basel). 2021;13:496.
   PubMed Web of Science ®Google Scholar
• Qin FX, Shao HY, Chen XC, et al. Knockdown of NPM1 by RNA interference inhibits cells proliferation and induces apoptosis in leukemic cell line. Int J Med Sci. 2011;8:287–294.
   PubMed Web of Science ®Google Scholar
• Andresen V, Erikstein BS, Mukherjee H, et al. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis. 2016;7:e2497.
   PubMed Web of Science ®Google Scholar
• Nabbouh AI, Hleihel RS, Saliba JL, et al. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia. Cancer. 2017;123:1662–1673.
   PubMed Web of Science ®Google Scholar
• Yang K, Wang M, Zhao Y, et al. A redox mechanism underlying nucleolar stress sensing by nucleophosmin. Nat Commun. 2016;7:13599.
   PubMed Web of Science ®Google Scholar
• Gionfriddo I, Brunetti L, Mezzasoma F, et al. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. Leukemia. 2021;35:2552–2562.
   PubMed Web of Science ®Google Scholar
• Šašinková M, Heřman P, Holoubek A, et al. NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization. Sci Rep. 2021;11:1084.
   PubMed Web of Science ®Google Scholar
• Penthala NR, Ketkar A, Sekhar KR, et al. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: anti-cancer agents that target nucleophosmin 1 (NPM1). Bioorg Med Chem. 2015;23:7226–7233.
   PubMed Web of Science ®Google Scholar
• Traver G, Sekhar KR, Crooks PA, et al. Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC. Cancer Lett. 2021;500:220–227.
   PubMed Web of Science ®Google Scholar
• De Cola A, Franceschini M, Di Matteo A, et al. N6l pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy. Cancer Lett. 2018;412:272–282.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Gionfriddo I, Mezzasoma F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125:3455–3465.
   PubMed Web of Science ®Google Scholar
• Nazha A, Bueso-Ramos C, Estey E, et al. The addition of All-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Front Oncol. 2013;3:218.
   PubMedGoogle Scholar
• Chi HT, Ly BT, Vu HA, et al. Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate. Asian Pac J Trop Biomed. 2014;4:570–574.
   PubMedGoogle Scholar
• Yi S, Wen L, He J, et al. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation. Ann Hematol. 2015;94:201–210.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao Z, Yi S, et al. Deguelin induced differentiation of mutated NPM1 acute myeloid leukemia in vivo and in vitro. Anticancer Drugs. 2017;28:723–738.
   PubMed Web of Science ®Google Scholar
• Forghieri F, Riva G, Lagreca I, et al. Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. Oncotarget. 2019;10:869–882.
   PubMedGoogle Scholar
• Greiner J, Schneider V, Schmitt M, et al. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood. 2013;122:1087–1088.
   PubMed Web of Science ®Google Scholar
• Casalegno-Garduño R, Meier C, Schmitt A, et al. Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation. Clin Dev Immunol. 2012;2012:146463.
   PubMedGoogle Scholar
• De Propris MS, Raponi S, Diverio D, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96:1548–1551.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Paschka P, Krzykalla J, et al. Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study. J Clin Oncol. 2020;38:623–632.
   PubMed Web of Science ®Google Scholar
• Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. 2020;136:3041–3050.
   PubMed Web of Science ®Google Scholar
• Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130:981–997.
   PubMed Web of Science ®Google Scholar
• Kühn MW, Song E, Feng Z, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6:1166–1181.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Tao W, Mak PY, et al. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood. 2021;138:1637–1641.
   PubMed Web of Science ®Google Scholar
• Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367:586–590.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4:4020–4027.
   PubMed Web of Science ®Google Scholar
• Testa U, Pelosi E, Castelli G. CD123 as a therapeutic target in the treatment of hematological malignancies. Cancers (Basel). 2020;11:1358.
   Web of Science ®Google Scholar
• Zhang S, Qin F, Yang L, et al. Nucleophosmin mutations induce chemosensitivity in THP-1 leukemia cells by suppressing NF-κB activity and regulating Bax/Bcl-2 expression. J Cancer. 2016;7:2270–2279.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791–803.
   PubMed Web of Science ®Google Scholar
• Tiong IS, Dillon R, Ivey A, et al. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukemia. Br J Haematol. 2021;192:1026–1030.
   PubMed Web of Science ®Google Scholar
• Cho H, Jang JE, Eom JI, et al. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukemia cells. Exp Hematol Oncol. 2021;10:28.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Lachowiez CA, Loghavi S, Kadia TM, et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020;4(7):1311–1320.
   PubMed Web of Science ®Google Scholar
• Prokoph N, Probst NA, Lee LC, et al. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. Blood. 2020;136:1657–1669.
   PubMed Web of Science ®Google Scholar
• Kuravi S, Cheng J, Fangman G, et al. Preclinical evaluation of Gilteritinib on NPM1-ALK-driven anaplastic large cell lymphoma cells. Mol Cancer Res. 2021;19:913–920.
   PubMed Web of Science ®Google Scholar
• Huang M, Garcia JS, Thomas D, et al. Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget. 2016;7:74917–74930.
   PubMedGoogle Scholar
• Mason EF, Kuo FC, Hasserjian RP, et al. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome. Am J Hematol. 2018;93:504–510.
   PubMed Web of Science ®Google Scholar
• Patel SS, Pinkus GS, Ritterhouse LL, et al. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019;94(8):921–928.
   PubMed Web of Science ®Google Scholar
• Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29:2709–2716.
   PubMed Web of Science ®Google Scholar
• Heiblig M, Duployez N, Marceau A, et al. The impact of DNMT3A status on NPM1 MRD predictive value and survival in elderly AML patients treated intensively. Cancers (Basel). 2021;13(9):2156.
   PubMed Web of Science ®Google Scholar
• Hubmann M, Köhnke T, Hoster E, et al. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica. 2014;99(8):1317–1325.
   PubMed Web of Science ®Google Scholar
• Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French Association Group. J Clin Oncol. 2017;35(2):185–193.
   PubMed Web of Science ®Google Scholar
• Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107–5111.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Versluis J, Passweg JR, et al. Comparative therapeutic value of post- remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia. 2015;29:1041–1050.
   PubMed Web of Science ®Google Scholar
• Karas M, Steinerova K, Lysak D, et al. Pre-transplant quantitative determination of NPM1 mutation significantly predicts outcome of aIlogeneic hematopoietic stem cell transplantation in patients with normal karyotype AML in complete remission. Anticancer Res. 2016;36(10):5487–5498.
   PubMed Web of Science ®Google Scholar
• Delsing Malmberg E, Johansson Alm S, Nicklasson M, et al. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML. Leuk Lymphoma. 2019;60(2):409–417.
   PubMed Web of Science ®Google Scholar
• Dillon R, Hills RK, Freeman SD, et al. Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study. Blood. 2020;135(9):680–688.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Middeke JM, Sockel K, et al. Minimal-residual disease guided treatment with azacitidine in MDS/AML patients at imminent risk of relapse: results of the prospective RELAZA2 trial. Blood. 2017;130:565.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131:1275–1291.
   PubMed Web of Science ®Google Scholar
• Pettersson L, Johansson Alm S, Almstedt A, et al. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia. Int J Lab Hematol. 2021;43(4):664–674.
   PubMed Web of Science ®Google Scholar
• Du Pisani LA, Shires K. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. Hematol Oncol Stem Cell Ther. 2015;8(3):106–114.
   PubMedGoogle Scholar
• Chopra A, Soni S, Pati H, et al. Nucleophosmin mutation analysis in acute myeloid leukemia: immunohistochemistry as a surrogate for molecular techniques. Indian J Med Res. 2016;143(6):763–768.
   PubMedGoogle Scholar
• Höllein A, Meggendorfer M, Dicker F, et al. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Adv. 2018;2(22):3118–3125.
   PubMed Web of Science ®Google Scholar